Corona Remedies IPO Date, Review, Price, Allotment Details

The Corona Remedies IPO will open on December 8, 2025, and close on December 10, 2025. It is a Book-Building Issue, through which the company plans to raise approximately ₹655.37 crores. This includes a fresh issue of ₹[.] crores and an Offer for Sale of up to 61,71,101 equity shares with a face value of ₹10 each.

The IPO price band is set between ₹1,008 and ₹1,062 per share. The allocation comprises 50% for QIBs, 35% for retail investors, and 15% for HNIs. The shares are expected to list on BSE and NSE on December 15, 2025, with allotment scheduled for December 11, 2025.

For FY 2025, the company reported revenue of ₹1,202.35 crores, up from ₹1,020.93 crores in 2024, and a profit of ₹149.43 crores, compared to ₹90.50 crores in 2024. Based on these financials, the IPO appears suitable for investors with a long-term perspective.

Corona Remedies IPO Details

IPO Open Date	December 8, 2025
IPO Close Date	December 10, 2025
Face Value	₹10 Per Equity Share
IPO Price Band	₹1008 to ₹1062 Per Share
Issue Size	Approx ₹655.37 Crores
Offer for Sale:	Approx 61,71,101 Equity Shares
Issue Type	Book Built Issue
IPO Listing	BSE, NSE
DRHP Draft Prospectus
RHP Draft Prospectus

Corona Remedies IPO Market Lot

The minimum market lot for the Corona Remedies IPO is 14 shares, requiring an application amount of ₹14,868. Retail investors can apply for up to 13 lots, totaling 182 shares, with a maximum investment of ₹1,93,284.

IPO Reservation

Corona Remedies IPO Anchor Investors

Anchor Bidding Date	December 5, 2025
Anchor Investors List
Shares Offered	[.] Shares
Anchor Size	[.] Cr.
lock-in period end date 50% shares (30 Days)	January 10, 2026
lock-in period end date 50% shares (90 Days)	March 11, 2026

Corona Remedies IPO Dates

The Corona Remedies IPO will open on December 8 and close on December 10. The allotment is scheduled to be finalized on December 11, with the shares expected to list on December 15.

Promoters and Holding Pattern

The promoters of the company are Dr. Kirtikumar Laxmidas Mehta, Niravkumar Kirtikumar Mehta, and Ankur Kirtikumar Mehta.

About Corona Remedies IPO

Founded in August 2004, Corona Remedies Limited is a leading pharmaceutical company engaged in the manufacturing and sale of products for women’s health, heart care, pain relief, urology, and other therapeutic areas. According to reports, it ranks as the 2nd largest company among 30 players in the Indian Pharmaceutical Market (IPM). As of December 31, 2024, the company employed 88 professionals in its R&D division.

Corona Remedies offers 67 brands across multiple therapeutic segments, including women’s healthcare, cardio-diabetes, pain management, urology, and multispecialty pharmaceuticals such as vitamins, minerals, nutrition, gastrointestinal, and respiratory products. The company has a pan-India presence with 2,598 medical representatives operating in 22 states and maintains two manufacturing facilities in Gujarat.

Corona Remedies IPO Company Financial Report

Amount ₹ in Crores

Corona Remedies IPO Valuation – FY2025

Check Corona Remedies IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.

Peer Group Comparison

IPO Lead Managers aka Merchant Bankers

• JM Financial Ltd.
• IIFL Capital Services Ltd.
• Kotak Mahindra Capital Co. Ltd.

Company Address

Corona Remedies Ltd.
CORONA House, C – Mondeal Business Park
Near Gurudwara S. G. Highway
Thaltej
Ahmedabad, Gujarat, 380059
Phone: +91 79 4023 3000
Email: complianceofficer@coronaremedies.com
Website: https://www.coronaremedies.com/

IPO Registrar

Bigshare Services Pvt. Ltd.
Phone: +91-22-6263 8200
Email: ipo@bigshareonline.com
Website: https://ipo.bigshareonline.com/IPO_Status.html